FDA Approved: RYLAZE — Supplemental Application (Jazz Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA entry describes a supplemental application for RYLAZE (asparaginase Erwinia chrysanthemi recombinant) submitted by Jazz Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• RYLAZE (ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN)

Snippet

SUPPL AP for RYLAZE (ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)-RYWN)